

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica




Fig. S1. Week-16 rates of percent improvement in EASI by baseline EASI, LEB vs PBO

Each chart shows rates of percent improvement in EASI ($\geq 50\%$, $\geq 75\%$, or $\geq 90\%$ reduction) in the LEB 250 mg Q2W group (purple) vs the PBO group (gray). Patients who received rescue medication or discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after treatment discontinuation due to any other reason were considered missing and were imputed using multiple imputation. Statistical tests were two-sided and were evaluated at a significance level of 0.05 using SAS software, version 9.4.

Abbreviations: CI, confidence interval; EASI, Eczema Area and Severity Index; LEB, lebrikizumab; PBO, placebo; Q2W, every two weeks; SAS, Statistical Analysis System.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$




Fig. S2. Week-16 rates of percent improvement in EASI by baseline IGA score, LEB vs PBO

Each chart shows rates of percent improvement in EASI ($\geq 50\%$, $\geq 75\%$, or $\geq 90\%$ reduction) in the LEB 250 mg Q2W group (purple) vs the PBO group (gray). Patients who received rescue medication or discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after treatment discontinuation due to any other reason were considered missing and were imputed using multiple imputation. Statistical tests were two-sided and were evaluated at a significance level of 0.05 using SAS software, version 9.4.

Abbreviations: CI, confidence interval; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; LEB, lebrikizumab; PBO, placebo; Q2W, every two weeks; SAS, Statistical Analysis System.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$




Fig. S3. Response rates at week 52 among week-16 LEB non-responders.

Each line shows EASI response rates among week-16 LEB non-responders who were assigned to the escape arm and received LEB 250 mg Q2W. Response rates at week 16 were greater than zero because some patients had achieved absolute EASI responses using rescue medication during the induction period. Data from weeks 16–52 are provided. Data were presented as observed cases, with no imputation for missing data.

Abbreviations: EASI, Eczema Area and Severity Index; LEB, lebrikizumab; Q2W, every two weeks.